The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Elkina A.Yu.

National Medical Research Center for Therapy and Preventive Medicine;
V.I. Razumovsky Saratov State Medical University

Sheptulina A.F.

National Medical Research Center for Therapy and Preventive Medicine

Drapkina O.M.

National Medical Research Center for Therapy and Preventive Medicine

Erythroferrone and its role in the iron metabolism regulation: molecular mechanisms and clinical significance

Authors:

Elkina A.Yu., Sheptulina A.F., Drapkina O.M.

More about the authors

Journal: Russian Journal of Preventive Medicine. 2025;28(10): 123‑128

DOI: 10.17116/profmed202528101123

Read: 804 times

Contact the author
Table of contents

ERYTHROFERRONE AND ITS ROLE IN THE IRON METABOLISM REGULATION: MOLECULAR MECHANISMS AND CLINICAL SIGNIFICANCE
ERYTHROFERRONE AND ITS ROLE IN THE IRON METABOLISM REGULATION: MOLECULAR MECHANISMS AND CLINICAL SIGNIFICANCE

To cite this article:

Elkina AYu, Sheptulina AF, Drapkina OM. Erythroferrone and its role in the iron metabolism regulation: molecular mechanisms and clinical significance. Russian Journal of Preventive Medicine. 2025;28(10):123‑128. (In Russ.)
https://doi.org/10.17116/profmed202528101123

 
Подписка 2026 Профилактическая медицина (Russian Journal of Preventive Medicine)
МСФ на ЯМ
Использование инфографики авторами научных работ
Recommended articles:
An expe­rience of the diva­lent iron drug use in blood donors. Russian Journal of Preventive Medi­cine. 2026;(2):85-89
Asse­ssment of iron levels in brain tissue in the context of chro­nic alco­hol into­xication. Fore­nsic Medi­cal Expe­rtise. 2026;(2):22-27
Abstract:

Erythroferrone (ERFE) is a protein that plays a key role in iron metabolic control in the body. It is synthesized predominantly in the spleen and bone marrow and has an effect on levels of hepcidin — a hormone that regulates the absorption of iron in the intestine and its redistribution in the body.

OBJECTIVE

To describe the role of erythroferrone in iron metabolic control, as well as possible molecular mechanisms underlying its action.

MATERIALS AND METHODS

A search for domestic and foreign publications on the studied topic in PubMed, RSCI and eLibrary databases was performed using the following keywords: «erythroferrone», «iron», «hepcidin», «ferroportin», «bone morphogenic protein». The depth of search was 14 years (2011—2024).

RESULTS

The mechanism of ERFE action consists in suppressing the expression of hepcidin, that contributes to increased iron availability for erythropoiesis, especially under conditions of anemia and hypoxia. In addition to its effect on iron metabolism, ERFE is also a myokine and participates in the regulation of muscle tissue regeneration and bone tissue metabolism. Studies show that ERFE has antioxidant activity, and this allows it to reduce the severity of inflammatory responses associated with impaired iron metabolism.

CONCLUSION

Understanding of the molecular mechanisms of erythroferrone action opens up prospects for developing new approaches in the treatment of diseases associated with iron deficiency or overload, as well as with musculoskeletal disorders.

Keywords:

erythroferrone
iron
hepcidin
ferroportin
myokine
bone morphogenic protein

Authors:

Elkina A.Yu.

National Medical Research Center for Therapy and Preventive Medicine;
V.I. Razumovsky Saratov State Medical University

Sheptulina A.F.

National Medical Research Center for Therapy and Preventive Medicine

Drapkina O.M.

National Medical Research Center for Therapy and Preventive Medicine

Received:

07.06.2025

Accepted:

05.08.2025

Close metadata

References:

  1. Lukina EA, Dezhenkova AV. Iron Metabolism in Normal and Pathological Conditions. Klinicheskaya onkogematolgiya. 2015;8(4):355-336. (In Russ.). https://doi.org/10.21320/2500-2139-2015-8-4-355-361
  2. Potemina TE, Volkova CA, Kuznetsova SV. General issues of iron metabolism and pathogenesis of iron deficiency anemia. Vestnik medicinskogo instituta «Reaviz»: reabilitaciya, vrach i zdorov’e. 2020;3(45):125-137. (In Russ.). Accessed May 10, 2025. https://eduherald.ru/ru/article/view?id=20962
  3. Cassat JE, Skaar EP. Iron in Infection and Immunity. Cell Host and Microbe. 2013;13:509-519.  https://doi.org/10.1016/j.chom.2013.04.010
  4. Camaschella C, Nai A, Silvestri L. Iron metabolism and iron disorders revisited in the hepcidin era. Haematologica. 2020;105(2):260-272.  https://doi.org/10.3324/haematol.2019.232124
  5. Pavlov AD, Morshchakova EF, Rumyancev AG. E`ritropoe`z, e`ritropoe`tin, zhelezo. M.: GEHOTAR-Media; 2011. (In Russ.).
  6. Budnevsky AV, Esaulenko IE, Ovsyannikov ES, et al. Anemic syndrome in patients with community-acquired pneumonia. Klinicheskaya medicina. 2016;94(1):56-60. (In Russ.). https://doi.org/10.18821/0023-2149-2016-94-1-56-60
  7. Bogdanov AN, Shcherbak SG, Lomonosova EV. Iron metabolism, iron deficiency anemia and cardiorenalanemia syndrome in in elderly and old patients. Vestnik Severo-Zapadnogo gosudarstvennogo medicinskogo universiteta im. I.I. Mechnikova. 2017;9(4):46-52. (In Russ.). https://doi.org/10.17816/mechnikov20179446-52
  8. Kadam S, Khaitan M, Banerjee P. Ferroportin-inhibitor salt: patent evaluation WO2018192973. Expert Opinion on Therapeutic Patents. 2021;31(7): 585-595.  https://doi.org/10.1080/13543776.2021.1928075
  9. Abboud S, Haile DJ. A novel mammalian iron-regulated protein involved in intracellular iron metabolism. Journal of Biological Chemistry. 2000;275(26): 19906-19912. https://doi.org/10.1074/jbc.M000713200
  10. Tsvetaeva NV, Levina AA, Mamukova YuI. Basics of regulation of iron metabolism. Klinicheskaya onkogematologiya. Fundamental’nye issledovaniya i klinicheskaya praktika. 2010;3:278-283. (In Russ.).
  11. Dev S, Babitt JL. Overview of iron metabolism in health and disease. Hemodialysis International. 2017;21:S6-20.  https://doi.org/10.1111/hdi.12542
  12. Yanatori I, Nishina S, Kishi F, et al. Newly uncovered biochemical and functional aspects of ferritin. FASEB Journal. 2023;37(8):e23095. https://doi.org/10.1096/fj.202300918R
  13. Zhang N, Yu X, Xie J, et al. New Insights into the Role of Ferritin in Iron Homeostasis and Neurodegenerative Diseases. Molecular Neurobiology. 2021;58(6):2812-2823. https://doi.org/10.1007/s12035-020-02277-7
  14. Tsiftsoglou AS. Erythropoietin (EPO) as a Key Regulator of Erythropoiesis, Bone Remodeling and Endothelial Transdifferentiation of Multipotent Mesenchymal Stem Cells (MSCs): Implications in Regenerative Medicine. Cells. 2021;10(8):2140. https://doi.org/10.3390/cells10082140
  15. Nicolas G, Chauvet C, Viatte L, et al. The gene encoding the iron regulatory peptide hepcidinis regulated by anemia, hypoxia, and infl ammation. Journal of Clinical Investigation. 2002;110(7):1037-1044. https://doi.org/10.1172/jci0215686
  16. Liu Q, Davidoff O, Niss K, et al. Hypoxia-inducible factor regulates hepcidin via erythropoietin-induced erythropoiesis. Journal of Clinical Investigation. 2012;122(12):4635-4644. https://doi.org/10.1172/jci63924
  17. Kautz L, Jung G, Valore E, et al. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nature Genetics. 2014;46:678-684.  https://doi.org/10.1038/ng.2996
  18. Vallet N, Club du Globule Rouge et du Fer. The role of erythroferrone in iron metabolism: From experimental results to pathogenesis. La Revue de Medecine Interne. 2018;39(3):178-184.  https://doi.org/10.1016/j.revmed.2017.05.008
  19. Zhang L, Xu P, Yan XY. Mechanism-based pharmacokinetic/pharmacodynamic modeling of erythroferrone in anemic rats with chronic kidney disease and chemotherapy-induced anemia: an early biomarker for hemoglobin response and rHuEPO hyporesponsiveness. ACS Pharmacology and Translational Science. 2025;8(1):189-202.  https://doi.org/10.1021/acsptsci.4c00575
  20. Srole DN, Ganz T. Erythroferrone structure, function, and physiology: Iron homeostasis and beyond. Journal of Cellular Physiology. 2021;236(7): 4888-4901. https://doi.org/10.1002/jcp.30247
  21. Wang CY, Xu Y, Traeger L, et al. Erythroferrone lowers hepcidin by sequestering BMP2/6 heterodimer from binding to the BMP type I receptor ALK3. Blood. 2020;135(6):453-456.  https://doi.org/10.1182/blood.2019002620
  22. Arezes J, Foy N, McHugh K, et al. Erythroferrone inhibits the induction of hepcidin by BMP6. Blood. 2018;132(14):1473-1477. https://doi.org/10.1182/blood-2018-06-857995
  23. Babar S, Saboor M. Erythroferrone in focus: emerging perspectives in iron metabolism and hematopathologies. Blood Science. 2024;16:6(4):e00198. https://doi.org/10.1097/BS9.0000000000000198
  24. Coffey R, Ganz T. Erythroferrone: An Erythroid Regulator of Hepcidin and Iron Metabolism. Hemasphere. 2018;2(2):e35.  https://doi.org/10.1097/HS9.0000000000000035
  25. Masheiko IV. Biochemical markers in assessing the processes of bone tissue remodeling in osteopenia and osteoporosis. Zhurnal Grodnenskogo gosudarstvennogo medicinskogo universiteta. 2017;15(2):149-153. (In Russ.).
  26. Chernykh TM, Volynkina AP, Gorshkov IP, et al. Disorders of bone metabolism in patients with thyroid dysfunction. Osteoporoz i osteopatii. 2016; 19(2):59-60. (In Russ.). https://doi.org/10.14341/osteo2016259-60
  27. Yaglova NV, Yaglov VV. Endocrine disruptors are a new etiological factor in bone diseases (review). Sovremennye tekhnologii v medicine. 2021;13(2):84-96. (In Russ.). https://doi.org/10.17691/stm2021.13.2.10
  28. Kawaguchi M, Kawao N, Takafuji Y, et al. Myonectin inhibits the differentiation of osteoblasts and osteoclasts in mouse cells. Heliyon. 2020;6(5):e03967. https://doi.org/10.1016/j.heliyon.2020.e03967
  29. Patent RF №RU 2684216 C2/04.04.2019. Ganz T, Nemet E, Kautc L. Eritroferron i Erfe-polipeptidy i sposoby regulyacii metabolizma zheleza. Accessed: 10 May 2025. (In Russ.).
  30. Sakhin VT, Madzhanova ER, Kryukov EV, et al. Anemia of Chronic Disease: Key Mechanisms of Pathogenesis in Patients with Malignancies and Feasible Classification Approaches. Clinical Oncohematology. 2019;12(3): 344-349. (In Russ.). https://doi.org/10.17650/1818-8346-2018-13-1-45-53
  31. Khachaturyan RA, Karavozova AE, Khidirova LD. Pathogenetic aspects of the influence of gliflozins on erythropoiesis and iron metabolism in patients with chronic heart failure. Lechashchij vrach. 2024;3:16-21. (In Russ.). https://doi.org/10.51793/OS.2024.27.3.002
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.